应用 MALDI-TOF-MS 分析对人白血病和神经胶质瘤细胞系的化疗耐药状态进行鉴别。

Discrimination of the chemotherapy resistance status of human leukemia and glioblastoma cell lines by MALDI-TOF-MS profiling.

机构信息

Unidad de Conocimiento Traslacional, Hospital de Alta Complejidad del Bicentenario Esteban Echeverría, San Martín 504, B1842, Monte Grande, Provincia de Buenos Aires, Argentina.

Cátedra de Inmunología, Departamento de Microbiología, Inmunología, Biotecnología y Genética, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires (UBA), Junín 956, C1113, Buenos Aires, Argentina.

出版信息

Sci Rep. 2023 Apr 5;13(1):5596. doi: 10.1038/s41598-023-32608-2.

DOI:10.1038/s41598-023-32608-2

PMID:37019937

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10076308/

Abstract

Chemotherapy mistreatment is partially due to a lack of rapid and reliable tools to discriminate between sensitive and resistant phenotypes. In many cases, the resistance mechanism is not fully understood, contributing to the diagnostic tools' absence. This work aims to determine the capacity of MALDI-TOF-MS profiling to discriminate between chemotherapy-resistant and sensitive phenotypes in leukemia and glioblastoma cells. A multivariate analysis of two therapy-resistant leukemia cell lines (Ki562 and Kv562) and two TMZ-resistant glioblastoma cell lines (U251-R and LN229-R) and their sensitive counterparts was performed. In this work, we first show MALDI-TOF-MS patterns analysis ability to differentiate these cancer cell lines by their chemotherapy-resistant status. We present a rapid and inexpensive tool that would guide and complement the therapeutic decision.

摘要

化疗药物滥用部分归因于缺乏快速且可靠的工具来区分敏感和耐药表型。在许多情况下，耐药机制尚未完全阐明，这也是缺乏诊断工具的原因之一。本研究旨在确定 MALDI-TOF-MS 分析能否区分白血病和神经胶质瘤细胞中的化疗耐药和敏感表型。对两种耐药性白血病细胞系（Ki562 和 Kv562）和两种 TMZ 耐药性神经胶质瘤细胞系（U251-R 和 LN229-R）及其相应的敏感细胞系进行了多元分析。在这项工作中，我们首先展示了 MALDI-TOF-MS 图谱分析能力，能够根据化疗耐药状态区分这些癌细胞系。我们提出了一种快速且廉价的工具，可用于指导和补充治疗决策。